Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation

Journal of Infectious Diseases

Volumn 180, Issue 4, 1999, Pages 1347-1350

  Raboud, J M ^a   Rae, S ^a   Hogg, R S ^a   Yip, B ^a   Sherlock, C H ^a   Harrigan, P R ^a   O'Shaughnessy, M V ^a   Montaner, J S G ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; INDINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; BRITISH COLUMBIA; CONFIDENCE INTERVALS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MALE; REAGENT KITS, DIAGNOSTIC; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; TIME FACTORS; VIRAL LOAD;

EID: 0033389460     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314998     Document Type: Article

References (10)

1. Carpenter CCJ, Fischl MA, Hammer SM, et al. Consensus statement: antiretroviral therapy for HIV infection in 1998. Recommendations of an international panel. JAMA 1998; 280:78-86.
2. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349:1086-92.
3. Raboud JM, Montaner JSG, Conway B, et al. Suppression of plasma viral load below 20 copies/mL is required to achieve a long-term response to therapy. AIDS 1998; 12:1619-24.
4. Raboud JM, Seminari E, Rae SL, et al. Comparison of costs of strategies for measuring levels of human immunodeficiency virus type 1 RNA in plasma by using Amplicor and Ultra Direct assays. J Clin Microbiol 1998; 36:3369-71.
5. Montaner JSG, Reiss P, Cooper D, et al. A randomized, double blinded trial comparing the immunologic and virologic effects of nevirapine, didanosine and zidovudine combinations among antiretroviral naive. AIDS-free. HIV-1 infected patients with CD4 counts between 300 and 600/mm'. JAMA 1998; 279:930-7.
6. Hogg RS, Rhone SA, Yip B, et al. Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy. AIDS 1998; 12:279-84.
7. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994; 32:292-300.
8. Mulder J, Resnick R, Saget B, et al. A rapid and simple method for extracting human immunodeficiency virus type 1 RNA from plasma: enhanced sensitivity. J Clin Microbiol 1997; 35:1278-80.
9. Kahn J, Mayers D, Riddler S, et al. Durable clinical and HIV-1 activity (60 weeks) and tolerability for efavirenz (DMP 266) in combination with indinavir (IDV): suppression to "<1 copy/mL" (OD = background) by Amplicor as a predictor of virologic treatment response (DMP 266-003, cohort IV) [abstract 692]. In: 5th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Chicago). Alexandria, VA: Foundation for Retrovirology and Human Health, 1998.
10. Kempf DJ, Rode RA, Yi X, et al. The duration of viral suppression during protease inhibitor therapy for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS 1998; 12:F9-14.